Australia community pharmacy | Readiness, delivery and the work between

A pharmacy owner, small-group services lead or authorised programme partner could be deciding whether to continue, adapt or extend a particular service. The initial brief should specify the service and the action available to the sponsor. The incentive is clearer capacity planning and a defensible account of delivery effort. We would not assume that a UK service design, payment model or workforce arrangement applies unchanged in Australia.

A first evaluation could examine a defined programme from available capacity through accepted work to completed activity and follow-up. Inputs might include authorised aggregate activity, rostered time, training status and reasons for incomplete work. The owner would define the beginning and end of an eligible service episode. The proposed PHARMORIS output would organise those observations into an inspectable review, leaving professional care and service delivery with the local team.

PBS statistics describe specified prescription and expenditure measures (Australian Government, n.d.). They can provide background, but they cannot establish an individual pharmacy’s service capacity, margin or clinical quality. We would keep public national information separate from the local evaluation sample and label the observation period. Changes in supply arrangements or dataset coverage would need checking before a trend is interpreted as a change in the number of people receiving appropriate care.

The review would separate launch effort from recurring delivery: training, staff cover, documentation, follow-up and exception handling. It would show whether a programme depends on an unusually committed individual or a process that other team members can maintain. Any financial scenario would use authorised local assumptions and distinguish claims submitted from cash received. More activity is not automatically more value if it consumes capacity needed for other appropriate pharmacy work.

We would stop if the programme definition is inconsistent, the sponsor cannot authorise the data or the reporting burden overwhelms the benefit. Continuation would require a specific decision that the review helps resolve and a feasible route into normal practice. The commercial conversation would concern that repeatable capability. It would not imply an Australian deployment, a government-funded pilot or an endorsement from a professional or public body.

Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.